NASDAQ:PRQR ProQR Therapeutics - PRQR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. $3.59 +0.17 (+4.97%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.40▼$3.7050-Day Range$2.63▼$3.6652-Week Range$0.53▼$3.85Volume1.04 million shsAverage Volume1.11 million shsMarket Capitalization$255.93 millionP/E RatioN/ADividend YieldN/APrice Target$3.90 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ProQR Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside8.6% Upside$3.90 Price TargetShort InterestHealthy3.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.97) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.27 out of 5 starsMedical Sector864th out of 995 stocksPharmaceutical Preparations Industry420th out of 482 stocks 1.4 Analyst's Opinion Consensus RatingProQR Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.90, ProQR Therapeutics has a forecasted upside of 8.6% from its current price of $3.59.Amount of Analyst CoverageProQR Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.50% of the float of ProQR Therapeutics has been sold short.Short Interest Ratio / Days to CoverProQR Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProQR Therapeutics has recently increased by 21.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProQR Therapeutics does not currently pay a dividend.Dividend GrowthProQR Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRQR. Previous Next 3.1 News and Social Media Coverage News SentimentProQR Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ProQR Therapeutics this week, compared to 1 article on an average week.Search Interest13 people have searched for PRQR on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.MarketBeat Follows11 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of ProQR Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.79% of the stock of ProQR Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ProQR Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProQR Therapeutics is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProQR Therapeutics is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProQR Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ProQR Therapeutics (NASDAQ:PRQR) StockProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.Read More Receive PRQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRQR Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Hold" from BrokeragesMarch 18, 2023 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Downgraded by StockNews.com to "Sell"March 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 14, 2023 | finance.yahoo.comProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA EditingMarch 7, 2023 | finance.yahoo.comProQR to Present at Upcoming Scientific and Industry ConferencesFebruary 28, 2023 | finance.yahoo.comProQR Therapeutics to Host Virtual R&D Event on March 29, 2023February 1, 2023 | finance.yahoo.comIndividual investors account for 45% of ProQR Therapeutics N.V.'s (NASDAQ:PRQR) ownership, while institutions account for 35%January 26, 2023 | finanznachrichten.deLilly, ProQR To Expand Licensing And Collaboration Deal For New Genetic MedicinesMarch 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.December 29, 2022 | msn.comBiotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & MoreDecember 23, 2022 | markets.businessinsider.comRaymond James Keeps Their Buy Rating on ProQR (PRQR)December 23, 2022 | finance.yahoo.comProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli LillyDecember 22, 2022 | markets.businessinsider.comDow Tumbles 300 Points; US Economy Expands 3.2% In Q3December 22, 2022 | markets.businessinsider.comJMP Securities Keeps Their Hold Rating on ProQR (PRQR)December 22, 2022 | benzinga.comProQR Therapeutics Shares Soar As Eli Lilly Expands RNA CollaborationDecember 22, 2022 | finance.yahoo.comProQR Announces Conference Call to Discuss Axiomer® RNA Editing PlatformNovember 15, 2022 | finance.yahoo.comProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022November 11, 2022 | finance.yahoo.comProQR Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 9, 2022 | finance.yahoo.comProQR Announces Third Quarter 2022 Operating and Financial ResultsNovember 3, 2022 | finance.yahoo.comProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare ConferenceSeptember 6, 2022 | reuters.comProQR Therapeutics NVAugust 12, 2022 | finance.yahoo.comRaymond James Bullish On This Penny Stock's Reprioritized PipelineAugust 12, 2022 | seekingalpha.comProQR upgraded at Raymond James on RNA-editing platformAugust 11, 2022 | finance.yahoo.comThis Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-EditingAugust 11, 2022 | seekingalpha.comProQR says EU regulator seeks additional trial for lead candidateAugust 11, 2022 | finance.yahoo.comProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology ProgramsAugust 4, 2022 | finance.yahoo.comProQR Announces Second Quarter 2022 Operating and Financial ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRQR Company Calendar Last Earnings11/04/2021Today3/27/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRQR CUSIPN/A CIK1612940 Webwww.proqr.com Phone(188) 166-7000FaxN/AEmployees1,504Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.90 High Stock Price Forecast$5.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+8.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,900,000.00 Net Margins-2,075.42% Pretax Margin-2,080.56% Return on Equity-76.32% Return on Assets-39.81% Debt Debt-to-Equity Ratio0.07 Current Ratio3.86 Quick Ratio3.86 Sales & Book Value Annual Sales$1.60 million Price / Sales159.96 Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book1.91Miscellaneous Outstanding Shares71,290,000Free Float65,303,000Market Cap$255.93 million OptionableOptionable Beta0.12 Key ExecutivesDaniel Anton de BoerChief Executive OfficerSheila SponseleeVice President, Head-People & OperationsJurriaan DekkersChief Financial OfficerGerard J. PlatenburgChief Scientific OfficerAniz GirachChief Medical OfficerKey CompetitorsKezar Life SciencesNASDAQ:KZRAcrivon TherapeuticsNASDAQ:ACRVThorne HealthTechNASDAQ:THRNAdicet BioNASDAQ:ACETOrganogenesisNASDAQ:ORGOView All CompetitorsInstitutional OwnershipMorgan StanleySold 99,063 shares on 2/15/2023Ownership: 0.531%Boothbay Fund Management LLCBought 90,285 shares on 2/15/2023Ownership: 0.127%Atom Investors LPSold 10,299 shares on 2/15/2023Ownership: 0.026%Mariner LLCBought 18,334 shares on 2/15/2023Ownership: 0.026%Belvedere Trading LLCBought 11,357 shares on 2/15/2023Ownership: 0.016%View All Institutional Transactions PRQR Stock - Frequently Asked Questions Should I buy or sell ProQR Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRQR shares. View PRQR analyst ratings or view top-rated stocks. What is ProQR Therapeutics' stock price forecast for 2023? 4 Wall Street analysts have issued 1 year target prices for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $2.00 to $5.00. On average, they expect the company's share price to reach $3.90 in the next year. This suggests a possible upside of 8.6% from the stock's current price. View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts. How have PRQR shares performed in 2023? ProQR Therapeutics' stock was trading at $3.70 on January 1st, 2023. Since then, PRQR stock has decreased by 3.0% and is now trading at $3.59. View the best growth stocks for 2023 here. Are investors shorting ProQR Therapeutics? ProQR Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,620,000 shares, an increase of 21.8% from the February 28th total of 1,330,000 shares. Based on an average daily trading volume, of 2,750,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 3.5% of the shares of the company are short sold. View ProQR Therapeutics' Short Interest. When is ProQR Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our PRQR earnings forecast. How were ProQR Therapeutics' earnings last quarter? ProQR Therapeutics (NASDAQ:PRQR) released its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.01. The biopharmaceutical company earned $1.03 million during the quarter, compared to analysts' expectations of $0.80 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 76.32% and a negative net margin of 2,075.42%. What ETF holds ProQR Therapeutics' stock ? Direxion mRNA ETF holds 19,698 shares of PRQR stock, representing 2.13% of its portfolio. What other stocks do shareholders of ProQR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX). What is ProQR Therapeutics' stock symbol? ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR." Who are ProQR Therapeutics' major shareholders? ProQR Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include M28 Capital Management LP (2.68%), Opaleye Management Inc. (2.05%), Marshall Wace LLP (0.59%), Morgan Stanley (0.53%), Two Sigma Investments LP (0.43%) and Millennium Management LLC (0.26%). How do I buy shares of ProQR Therapeutics? Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ProQR Therapeutics' stock price today? One share of PRQR stock can currently be purchased for approximately $3.59. How much money does ProQR Therapeutics make? ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $255.93 million and generates $1.60 million in revenue each year. The biopharmaceutical company earns $-72,900,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis. How many employees does ProQR Therapeutics have? The company employs 1,504 workers across the globe. How can I contact ProQR Therapeutics? ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com. This page (NASDAQ:PRQR) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.